Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of Rio Grande do Sul
• Collaborator: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
• Treatments: Resveratrol

Criteria

Inclusion Criteria:

Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months.

Exclusion Criteria:

Patients will be excluded from the study:

• Have a diagnosis of diabetes

• Use other antipsychotic drugs, clozapine beyond

• Using medicines for diabetes or dyslipidaemia

• Accept not participate in any stage of the research.